676 related articles for article (PubMed ID: 36110853)
1. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M; Jabbari A
Front Immunol; 2022; 13():955035. PubMed ID: 36110853
[TBL] [Abstract][Full Text] [Related]
2. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib for the Treatment of Alopecia Areata.
Freitas E; Guttman-Yassky E; Torres T
Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
6. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells.
Kim JE; Lee YJ; Park HR; Lee DG; Jeong KH; Kang H
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698510
[TBL] [Abstract][Full Text] [Related]
7. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Yu L; Yu H; Zhang S; Hao Y; Zhang S
Front Immunol; 2022; 13():904156. PubMed ID: 35795663
[TBL] [Abstract][Full Text] [Related]
9. Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.
Zheng C; Tosti A
Dermatol Clin; 2021 Jul; 39(3):407-415. PubMed ID: 34053594
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
11. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
Passeron T; King B; Seneschal J; Steinhoff M; Jabbari A; Ohyama M; Tobin DJ; Randhawa S; Winkler A; Telliez JB; Martin D; Lejeune A
Front Immunol; 2023; 14():1243556. PubMed ID: 38022501
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-15 is a hair follicle immune privilege guardian.
Suzuki T; Chéret J; Scala FD; Rajabi-Estarabadi A; Akhundlu A; Demetrius DL; Gherardini J; Keren A; Harries M; Rodriguez-Feliz J; Epstein G; Lee W; Purba T; Gilhar A; Paus R
J Autoimmun; 2024 May; 145():103217. PubMed ID: 38581915
[TBL] [Abstract][Full Text] [Related]
14. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.
Xing L; Dai Z; Jabbari A; Cerise JE; Higgins CA; Gong W; de Jong A; Harel S; DeStefano GM; Rothman L; Singh P; Petukhova L; Mackay-Wiggan J; Christiano AM; Clynes R
Nat Med; 2014 Sep; 20(9):1043-9. PubMed ID: 25129481
[TBL] [Abstract][Full Text] [Related]
15. Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata.
Dai Z; Sezin T; Chang Y; Lee EY; Wang EHC; Christiano AM
Front Immunol; 2022; 13():955038. PubMed ID: 36203601
[TBL] [Abstract][Full Text] [Related]
16. [Janus kinase inhibitors for the treatment of alopecia areata].
Kobal I; Ramot Y
Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
18. Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
Sardana K; Bathula S; Khurana A
Indian Dermatol Online J; 2023; 14(4):465-474. PubMed ID: 37521227
[TBL] [Abstract][Full Text] [Related]
19. JAK Inhibitors for Treatment of Alopecia Areata.
Wang EHC; Sallee BN; Tejeda CI; Christiano AM
J Invest Dermatol; 2018 Sep; 138(9):1911-1916. PubMed ID: 30057345
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
Ismail FF; Sinclair R
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
[No Abstract] [Full Text] [Related]
[Next] [New Search]